A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML less than or equal to 60 Years of Age.

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML less than or equal to 60 Years of Age.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Sorafenib (Primary) ; Cytarabine; Daunorubicin; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms SORAML
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Nov 2015 Final results published in the Lancet Oncology
    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top